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Multiple sclerosis (MS) refers to a condition in which there is an immune­mediated                         
attack on the central nervous system (CNS). This attack damages the myelin on the neurons and                 
causes sclerosis (scar tissue) that disrupts neural signal transmission.​1 The constellation of                       
demyelinated neurons, degeneration, and sclerosis forms histopathologically characteristic               
inflammatory plaques.​2 This paper evaluates three randomized controlled trials (RCTs)                   
comparing the efficacy of cooling therapy to placebo for improving functional mobility in adults                           
with MS.  
While the prevalence of MS has not been definitely established, it is thought to affect                             
400,000 people in the U.S. and 2.3 million globally.​3 The symptoms of fatigue, spasticity, and                             
heat­sensitivity are interrelated and have a predominant role in determining the impact of MS on                             
patients’ activities of daily living.​4 Additionally, the disease presents a financial burden for                         
patients and for society as a whole. The total cost of MS for the average patient is estimated to be                                       
$8528−$54,244 annually, and the condition costs the United States approximately $28 billion per                         
year.​5 In fact, due to prescription drug costs and to the early onset of the disease, MS is the                                     
second costliest chronic condition (following congestive heart failure).​5 
The etiology of MS remains elusive; various triggers, such as viruses and environmental                         
factors with coexisting immunodeficiency, are supported in the literature.​2 While the symptoms                       
and disease course in MS vary on an individual basis, patients with relapsing­remitting multiple                           
sclerosis (RRMS) are known to have elevated body temperature, even at rest.​1 In these patients,                             
this state is associated with fatigue (general and physical), a phenomenon originally described by                           
Wilhelm Uhthoff.​6 
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Treatment of MS can include both symptomatic and disease­modifying components. The                     
approach to therapy and specific medications chosen depend on the clinical picture as well as on                               
the patient’s preferences and input. Symptomatic treatment may include SSRIs (depression),                     
muscle relaxants (spasticity), and anticholinergic agents (bladder urgency). Addressing the                   
psychosocial impact of the disease is an essential component. Various disease­modifying                     
treatments are approved for MS. These include interferons (e.g. IFN­ß1b [Betaseron]),                     
immunomodulators (e.g. glatiramer acetate [Copaxone]), and monoclonal antibodies (e.g.                 
natalizumab [Tysabri]).​7 
Because symptomatic treatment does not, as a rule, affect the course of the disease,                           
patients may reasonably feel that potential adverse effects associated with these measures                       
outweigh their benefits.​7 Furthermore, it seems logical that therapies capable of ameliorating                       
symptoms without negatively impacting quality of life would be desirable for patients.  
Since the observations of Uhthoff in 1890, exercise has been associated with transient                         
worsening of MS symptoms in most patients (up to 80%). The etiology behind this exacerbation                             
was traced to hyperthermia several decades ago.​8 Despite this history, the efficacy of cooling                           
therapy in symptomatic relief has not been firmly established in the literature. While cooling                           
therapy does not offer disease modification, it may have promise as a safe method of alleviating                               
symptoms and encouraging health­promoting behaviors such as aerobic exercise. Additionally,                   




The objective of this selective EBM review is to determine whether or not cooling                           
therapy improves functional mobility in heat­sensitive adults diagnosed with MS. 
METHODS 
Three randomized controlled trials were used in this review. Adults with heat­sensitive                       
multiple sclerosis comprise the population in the studies used. The experimental intervention in                         
each study was a form of cooling therapy, although each used a different device to achieve                               
cooling. One study used bilateral thigh­cuffs that used fluid evaporation to remove body heat.​9                           
Another employed an elastic wrist sleeve with a vacuum pump to create a negative                           
(subatmospheric) pressure gradient inside the chamber.​10 In the third study, a specialized hood                         
used circulating fluid to conduct heat away from the participant’s head and neck.​11 This                           
intervention was compared to a control, consisting of either an absence of cooling or sham                             
cooling (in which the participants were fitted with a device they were told was removing body                               
heat). The outcome for all participants was one or more objective measurements of functional                           
capability.  
All articles reviewed herein were published in the English language and in peer­reviewed                         
journals. A PubMed search was performed using the keywords cooling and multiple sclerosis.                         
Articles were selected based on relevance to the aforementioned objective and on whether the                           
measured outcome was patient­oriented rather than disease­oriented. The inclusion criteria                   
consisted of RCTs published no earlier than 1999. Studies in the chosen articles excluded those                             
younger than 18 years of age, those with relevant concomitant conditions (e.g. infections,                         
pregnancy), and those with a recent MS exacerbation or relapse. Reported statistics were                         
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p​­values, paired ​t​­test, and one­ and two­way analysis of variance (ANOVA). Table 1                         
summarizes the demographics of each study. 
Table 1 – Demographics & Characteristics of Included Studies 













































































Meyer­Heim, et al., in their single­blinded balanced crossover study, compared each                     
participant’s performance on a number of functional examinations with activated thigh­cuff                     
cooling to their performance with sham (inactivated) cooling.​9 These examinations included the                       
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MS functional composite (MSFC)(consisting of walking capacity, manual dexterity, and                   
cognition) as well as in terms of postural control, knee spasticity (Modified Ashworth Scale),                           
muscle strength of foot dorsal flexion, knee flexion (McMesin Pull Gauge), and grip strength                           
(Jamar dynamometer).  
In a similar study using randomized paired trials, Grahn, et al. measured their subjects’                           
exercise duration on a standardized treadmill protocol with the stop criteria of symptom                         
exacerbation and subjective fatigue.​10 Under this protocol, the speed and slope on the treadmill                           
were alternately increased by consistent increments at three minute intervals. A baseline                       
assessment (without cooling) was completed as a control, and one or more experimental trials                           
with cooling via wrist cuff device were completed two to seven days after the previous trial.  
Lastly, Reynolds, et al. conducted a double­blinded crossover study in which participants                       
underwent a battery of tests three times under different conditions: true cooling via specialized                           
hood, sham cooling, and no cooling; the participants were told that they would undergo two                             
cooling trials in order to blind them to the presence of sham cooling.​11 The tests of functional                                 
mobility included in this battery were the six­minute walk test, the 25­foot walk test, and the                               
timed up and go test.​11 The performance measurements (with parameters determined by the                         
nature of each test) were then compared across the three conditions. 
RESULTS 
Three RCTs compared functional mobility with and without a cooling stimulus in                       
heat­sensitive adults diagnosed with MS. Meyer­Heim, et al. studied 20 adults from 27 to 66                             
years of age (mean 48.7 years). Each participant completed paired trials, one with activated                           
cooling and one with inactivated sham cooling as a control. The study was single­blinded; the                             
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participants, but not the researchers, were blinded to which of the two trials was experimental.                             
During each trial, the participants underwent a number of tests of functional mobility, the results                             
of which are continuous data. No participants were said to be lost to follow­up. Tympanic                             
temperature was not significantly altered between the active and sham cooling trials (Table 2).                           
Skin temperature was ~4°C lower during the active cooling trials; the authors do not comment on                               
the significance of this deviation. Significant improvement was noted in the 25­foot walk,                         
nine­hole peg test (a test of manual dexterity), and the total MSFC ( ​p < 0.05). According to the                                   
participants, the cooling device was without adverse effects. 
Table 2 – Meyer­Heim, et al.: Treatment vs. Control Trials 
Outcome measure  Active cooling  Sham control  P​ value 









































Grahn, et al. studied 12 adults from 42 to 63 years of age (mean 50.8 years). Two                                 
subjects were lost to follow­up as they withdrew from the study due to self­reported relapse. As                               
above, each participant completed paired trials. In this study, one trial was with cooling and the                               
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other was without cooling; no sham cooling condition was used. Neither the participant nor the                             
researchers were blinded to the presence or absence of cooling during each trial. During each                             
trial, participants exercised until reaching a stop criterion (subjective fatigue or symptom                       
exacerbation), and the duration of exercise was recorded as continuous data. With the studied                           
intervention, exercise duration increased significantly as a group ( ​p < 0.003, paired ​t​­test)(Table                         
3) and improved for each subject. Body temperature was not measured and therefore could not                             
be compared between the cooling and control trials. Adverse effects of cooling were not                           
explicitly reported. However, a change in usual symptoms was reported by “several” subjects,                         
who stated that, during cooling, their symptoms occurred in waves rather than as progressive                           














1  4.8  5 – 6  3  17.2  22.9  1.34 
2  0.8  0  1  20.0  32.0  1.60 
3  4.0  5 – 6  3  20.7  22.1  1.07 
4  1.3  0  1  25.0  28.3  1.13 
5  3.2 – 4.8  6  4  36.4  44.8  1.23 
6  4.8  7 – 8.5  3  37.4  49.8  1.33 
7  4.0  6 – 7  5  38.4  51.6  1.34 
8  2.4  0  2  39.8  43.2  1.09 
9  3.2  0  2  39.9  67.5  1.69 
10  3.2  5.5 – 6  2  42.3  65.8  1.55 
Robinaugh, Cooling Therapy in Multiple Sclerosis 8 




Reynolds, et al. studied six adults with a mean age of 41.3 ± 7.3 years; while all                                 
participants in this study were female, the authors report that this gender distribution was not by                               
design. No subjects were reported as lost to follow­up. Participants completed a battery of tests                             
under three conditions: true cooling, sham cooling, and no cooling. A physiotherapist conducted                         
the battery of tests and was blinded to under which condition each trial was performed; the                               
participants were also blinded to true and sham cooling. After resting for 20 minutes, participants                             
were fitted with a cooling hood for 60 minutes, regardless of the presence of actual cooling or                                 
not. Following another rest period for 10 minutes, subjects began the tests. All data obtained                             
were continuous. Body temperature (measured rectally) was found to be 0.37°C lower in the true                             
cooling condition vis­à­vis sham and no cooling ( ​p < 0.01). ANOVA was performed on the trials                               
to determine statistical significance of outcomes measured (Table 4). In terms of the tests of                             
functional mobility, a significant difference ( ​p = 0.036) was found between true cooling and                           
sham or no cooling on the six­minute walk test. Comparing true and sham cooling to the no                                 
cooling condition, there was also a significant improvement ( ​p = 0.004) on the timed up and go.                                 





Table 4 – Reynolds, et al.: Summary of Mean (SD) Performance Measurements &                       
Statistical Comparisons Across the No, Sham, and True Cooling Conditions 
  True Cooling  Sham Cooling  No Cooling 
25­foot walk test (seconds) 
F​ = 2.462 & ​P​ = 0.13  5.80 (1.54)  5.82 (1.54)  6.10 (1.61) 
Timed up and go (seconds) 
F​ = 11.21 & ​P ​= 0.0036  11.53 (4.63) ​








Because cooling therapy did not elicit any adverse effects in any of the three studies                             
included in this review, it appears to be a well­tolerated approach to managing symptoms of MS.                               
However, long­term evaluation of its safety cannot be inferred from these studies, as all                           
participants were evaluated and surveyed soon after the experimental intervention was                     
completed. Additionally, the three studies used different devices to achieve a cooling effect; still                           
more devices are commercially available, including cooling vests.​12 The safety of one device                         
should not be understood as representing the safety of another. For example, some devices may                             
reach significantly lower temperatures that could potentially cause some type of hypothermic                       
injury. Finally, specific parameters (e.g. indications, contraindications) for the use of cooling                       
therapy would ideally be developed before its widespread clinical application. 
One common barrier with which patients are faced when starting a nonstandard therapy                         
for a given condition is payment, as many patients are unable to cover their medical costs                               
without financial assistance. The Multiple Sclerosis Association of America (MSAA) currently                     
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offers “cooling and assistive equipment” (including cooling vests) for people diagnosed with MS                         
who complete an online application and meet household income requirements.​12 Health                     
insurance companies may not pay for cooling therapy, considering it experimental or not covered                           
by certain specific coverage plans.  
There are several limitations of the studies included in this review, some of which were                             
explicitly mentioned within the respective text. Only Reynolds, et al. used a three­armed                         
approach to evaluate differences between true cooling, sham cooling, and no cooling. In the                           
study by Grahn, et al., failing to blind participants (as well as researchers) to their testing                               
condition (i.e. the absence of sham cooling trials) introduces the confounding factor of a placebo                             
effect. Meyer­Heim, et al. used a single­blinded approach in which the assessment raters were                           
aware of the cooling condition (i.e. true or sham) of each trial, and it cannot be ruled out that this                                       
knowledge impacted the results of the study. For example, the raters could have subtly and                             
unintentionally encouraged participants when they were known to be under the experimental                       
condition.  
Another challenge associated with blinding in this nature of research is that, in the study                             
by Meyer­Heim, et al., the vast majority of participants (90%) were able to identify the sham                               
cooling condition correctly. Reynolds, et al. addressed this issue by intermittently running cold                         
fluid through the cooling hood during the sham cooling trials; this was reported as conveying a                               
sensation of cold without actually affecting body temperature. However, they did not indicate                         
whether participants were unable to discern sham from true cooling. 
A limitation shared by all studies reviewed herein is small sample size (n​1 = 20, n​2 = 12,                                   
n​3 = 6). Grahn, et al. addressed this limitation through repeated trials with the same participants.                               
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In their trial of 12 subjects (less 2 who were lost to follow­up), 88 trials were completed, with 26                                     
data sets meeting the criteria for paired trials. As more data are gathered on cooling therapy with                                 
presumably promising results for MS, it would strengthen the body of evidence for studies to                             
progressively enlarge their sample sizes. 
This review of cooling therapy for heat­sensitive adults diagnosed with MS is inherently                         
limited in itself. First, covering more than three studies would have been outside its established                             
scope. Furthermore, only RCTs from a single database were included, which may not necessarily                           
be representative of the entire current body of research. Other forms of research (e.g. case                             
studies) were excluded due to the associated less rigorous standards and higher potential for                           
confounding factors. Finally, while studies published prior to 1999 may have been informative,                         
they were excluded in the interest of conducting an up­to­date evaluation. 
CONCLUSION 
Based on the best currently available evidence, cooling therapy appears to be effective in                           
improving functional mobility in heat­sensitive adults with a diagnosis of MS. Future studies are                           
needed to determine the optimum protocol (i.e. the ideal temperature, timing of cooling, etc.) and                             
device (e.g. thigh­cuff vs. cooling hood vs. wrist sleeve) for this therapy. Alternate methods of                             
blinding would benefit further research in order to control for placebo. To achieve this end,                             
Grahn, et al. suggest experimental use of nerve blocks to eliminate cutaneous afferent input,                           
following establishment of cooling therapy as effective. This intervention seems appropriate now                       
in light of the demonstrated shortcomings of sham cooling for blinding.  
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